Mechanisms of immunomodulatory effects of mesenchymal stem cells



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Mesenchymal stem cells play different roles in organism
and are capable to differentiate into mesenchymal cells line
(osteoblasts, chondrocytes, adipocytes) and other cell lines.
MSCs also can interact (directly and indirectly) with almost
all cells of immune system via soluble factors and cell-contact
interactions and substantially modulate immune response of
an organism. MSCs can be applied in medical practice as the
safe immunosuppressive agent for allogenic transplantation
and for treatment of autoimmune diseases. This review
deals with interactions between MSCs and immune cells and
mechanisms of MSC-induced immunosuppression.

About the authors

D I Ivanyuk,

V.K. Gusak Institute of Urgent and Reparative Surgery NAMS, Donetsk, Ukraine

V.K. Gusak Institute of Urgent and Reparative Surgery NAMS, Donetsk, Ukraine

V V Turchin,

V.K. Gusak Institute of Urgent and Reparative Surgery NAMS, Donetsk, Ukraine

V.K. Gusak Institute of Urgent and Reparative Surgery NAMS, Donetsk, Ukraine

A G Popandonulo,

V.K. Gusak Institute of Urgent and Reparative Surgery NAMS, Donetsk, Ukraine

V.K. Gusak Institute of Urgent and Reparative Surgery NAMS, Donetsk, Ukraine

V K Grin

V.K. Gusak Institute of Urgent and Reparative Surgery NAMS, Donetsk, Ukraine

V.K. Gusak Institute of Urgent and Reparative Surgery NAMS, Donetsk, Ukraine

References

  1. Pittenger M.F., Mackay A.M., Beck S.C. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-7.
  2. Le Blanc K., Frassoni F., Ball L. at al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-86.
  3. Sun L., Akiyama K., Zhang H. at al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009; 27(6): 1421-32.
  4. Liang J., Zhang H., Hua B. at al. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Multiple Sclerosis 2009; 15(5): 644-6.
  5. DelaRosa O., Lombardo E., Beraza A. at al. Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng. 2009; 15(10): 2795-806.
  6. Zappia E., Casazza S., Pedemonte E. at al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106: 1755-61.
  7. Sheng H., Wang Y., Jin Y. at al. A critical role of IFNγ in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Research 2008; 18: 846-57.
  8. Liotta F., Angeli R., Cosmi L. at al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 2008; 26(1): 279-89
  9. English K., Ryan J.M., Tobin L. at al. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin. Exp. Immunol. 2009; 156(1): 149-60.
  10. Nemeth K., Leelahavanichkul A., Yuen P.S. at al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 2009; 15(1): 42-9.
  11. Yang S.H., Park M.J., Yoon I.H. at al. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp. Mol. Med. 2009; 41(5): 315-24.
  12. Zhao Z.G., Li W.M., Chen Z.C. et al. Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patients with chronic myeloid leukemia. Immunol. Invest. 2008; 37(7): 726-39.
  13. Sato K., Ozaki K., Oh I. at al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells Blood 2007; 109(1): 228-34.
  14. Ren G., Zhang L., Zhao X. at al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-50.
  15. Chabannes D., Hill M., Merieau E. at al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 2007; 110: 3691-4. 14. Selmani Z., Naji A., Zidi I. at al. Human leukocyte
  16. Selmani Z., Naji A., Zidi I. at al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26: 212-22.
  17. Honczarenko M., Le Y., Swierkowski M. at al. Human BMSC express a distinct set of biologically functional chemokine receptors. Stem Cells 2006; 24: 1030-41.
  18. Selmani Z., Naji A., Gaiffe E. at al. HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Transplantation 2009; 87 Suppl 9: 62-6.
  19. Glennie S., Soeiro I., Dyson P.J. et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105(7): 2821-7.
  20. Ren G., Su J., Zhang L. at al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009; 27(8): 1954-62.
  21. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-22.
  22. Petrini I., Pacini S., Petrini M. at al. Mesenchymal cells inhibit expansion but not cytotoxicity exert
  23. Petrini I., Pacini S., Petrini M. at al. Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells. Eur. J. Clin. Invest. 2009; 39(9): 813-8.
  24. Rasmusson I., Ringden O., Sundberg B. et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76: 1208-13
  25. Guo Z., Zheng C., Chen Z. at al. Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells. Eur. J. Immunol. 2009; 39(10): 2840-9.
  26. Rafei M., Campeau P.M., Aguilar-Mahecha A. at al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J. Immunol. 2009; 182(10): 5994-6002.
  27. Nemeth K., Keane-Myers A., Brown J.M. at al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. PNAS USA 2010; 107(12): 5652-7.
  28. English K., Barry F.P., Field-Corbett C.P. et al. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol. Lett. 2007; 110(2): 91-100.
  29. Augello A., Tasso R., Negrini S.M. at al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 2005; 35(5): 1482-90.
  30. Ren G., Zhao X., Zhang L. at al. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J. Immunol. 2010; 184(5): 2321-8.
  31. Krampera M., Cosmi L., Angeli R. at al. Role for interferongamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386-98.
  32. Opitz C.A., Litzenburger U.M., Lutz C. at al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine- 2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 2009; 27(4): 909-19.
  33. Nemeth K., Mayer B., Mezey E. Modulation of bone marrow stromal cell functions in infectious diseases by toll-like receptor ligands. J. Mol. Med. 2010; 88(1): 5-10.
  34. Karlsson H., Samarasinghe S., Ball L.M. at al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 2008; 112(3): 532-41.
  35. Sotiropoulou P.A., Perez S.A., Gritzapis A.D. at al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74-85.
  36. Corcione A., Benvenuto F., Ferretti E. at al. Human mesenchymal stem cells modulate B-cell function. Blood 2006; 107: 367-72.
  37. Rafei M., Hsieh J., Fortier S. at al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 2008; 112: 4991-8.
  38. Djouad F., Charbonnier L.M., Bouffi C. at al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem cells 2007; 25: 2025-32.
  39. Jiang X.X., Zhang Y., Liu B. at al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105(10): 4120-26.
  40. Spaggiari G.M., Abdelrazik H., Becchetti F. at al. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSCderived prostaglandin E2. Blood 2009; 113: 6576-83.
  41. Raffaghello L., Bianch G., Bertolotto M. at al. Human mesenchymal stem cells inhibit neutriphil apoptosis: a model for neutrophil preservation in the bone marrow nishe. Stem Cells 2008; 26: 151-62.
  42. Chan J.L., Tang K.C., Patel A.P. et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 2006; 107(12): 4817-24.
  43. Stagg J., Pommey S., Eliopoulos N. at al. IFNγ-stimulated marrow stromal cells: a new type of non-hematopoetic antigen presenting cells. Blood 2006; 107: 2570-77.
  44. Zangi L., Margalit R., Reich-Zeliger S. et al. Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells 2009; 27(11): 2865-74.
  45. Ortiz L.A., Dutreil M., Fattman C. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. PNAS USA 2007; 104(26): 11002-7. 45. Nemeth K., Keane-Myers A., Brown J. et al. Bone marrow
  46. Nemeth K., Keane-Myers A., Brown J. et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. PNAS USA 2010; 107(12): 5652-7.
  47. Boumaza I., Srinivasan S., Witt W.T. et al. Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. J. Autoimmun. 2009; 32(1): 33-42.
  48. Zheng Z.H., Li X.Y., Ding J. et al. Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Rheumatology 2008; 47(1): 22-30.
  49. Osiris Therapeutics Inc. PI Linda Custer. Prochymal™ adult human mesenchymal stem cells for treatment of moderate-to-severe Crohns disease. http://clinicaltrials.gov/ct2/show/NCT00294112?ter m=NCT00294112&rank=1
  50. The affiliated nanjing drum tower hospital of Nanjing university medical school (PI Lingyun Sun, MD). Allogeneic mesenchymal stem cells transplantation for primary Sjögrens syndrome (pSS). http://clinicaltrials. gov/ct2/show/NCT00953485?term=NCT00953485&rank=1
  51. Nanjing medical university, national natural science foundation of China (PI Lingyun Sun, MD). Mesenchymal stem cells transplantation for refractory systemic lupus erythematosus (SLE). http://clinicaltrials. gov/ct2/show/NCT00698191?term=NCT+00698191&rank=1
  52. The affiliated nanjing drum tower hospital of Nanjing university medical school (PI Lingyun Sun, MD). Allogeneic mesenchymal stem cells transplantation for systemic sclerosis (SSc). http://clinicaltrials. gov/ct2/results?term=NCT+00962923
  53. Tsuji H., Miyoshi S., Ikegami Y. et al. Xenografted human amniotic membrane-derived mesenchymal stem cells are immunologically tolerated and transdifferentiated into cardiomyocytes. Circ. Res. 2010; 106(10): 1613-23.
  54. Djouad, F., Plence P., Bony C. et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102(10): 3837-40.
  55. Karnoub A.E., Dash A.B., Vo A.P. et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557-63.
  56. Patel S.A., Meyer J.R., Greco S.J. et al. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J. Immunol. 2010; 184(10): 5885-94.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies